Ontario narrows out-of-country drug funding rules after cancer patient court victory
The revised rules limit funding abroad to cases where treatment is already covered in Ontario or delay could cause death or irreversible harm, officials said.
- On Tuesday, Oct. 6, 2026, Ontario announced legislative amendments to clarify out-of-country drug funding policies, effectively barring coverage for treatments like the one sought by 37-year-old Alex Shved for Stage 4 melanoma.
- Previously, the Ontario Superior Court of Justice quashed the province's denial for Shved, who seeks tumour-infiltrating lymphocyte therapy in the United States; the treatment costs US$515,000 and is under review for public funding in Canada.
- Ontario officials stated the change prevents financial exposure, arguing that funding out-of-country treatments during local reviews could "undermine the incentive structure that encourages manufacturers to participate in Canada's drug review processes."
- Shved called the move "incredibly disappointing," expressing frustration with Premier Doug Ford and Health Minister Sylvia Jones, while Jones stated the regulatory change "protects the integrity of Ontario's world-class drug approval process."
- While the new rules bar Shved's specific treatment, the government says it is "exploring all available options," including a "mutually satisfactory resolution" in his individual case, though his request was rejected a third time.
19 Articles
19 Articles
This Ontario man won a court case for Stage 4 cancer treatment in the U.S. Then the province changed the rules
Alex Shved took the province to court after OHIP rejected his oncologist's request to receive urgent treatment in the U.S. Despite the court win, he says the province has effectively blocked access to pubic funding for out-of-country drug treatments.
The Toronto Star
Ontario narrows out-of-country drug funding rules after cancer patient court victory
TORONTO - An Ontario man with Stage 4 melanoma says the province has effectively blocked access to public funding for out-of-country drug treatments in response to his attempts to urgently
Ontario clarifies out-of-country drug funding process
The Ontario government has aligned Regulation 552 of the Health Insurance Act with the province’s long-standing out-of-country drug funding policy, which has been in place since 2011, in order to protect the province’s ability to provide affordable, publicly funded medication for Ontario patients at home. The policy only funds drug treatments that have undergone Ontario’s […]
Coverage Details
Bias Distribution
- 81% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
